Basal insulin and cardiovascular and other outcomes in dysglycemia

Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle, Lars E Rydén, Salim Yusuf, ORIGIN Trial Investigators, Thure Krarup, Hans Jørgen Duckert Perrild, Christian Tobias Torp-Pedersen


The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested.
Original languageEnglish
JournalNew England Journal of Medicine
Issue number4
Pages (from-to)319-28
Number of pages10
Publication statusPublished - 2012


  • Aged
  • Blood Glucose
  • Cardiovascular Diseases
  • Cholesterol
  • Diabetes Mellitus, Type 2
  • Double-Blind Method
  • Drug Therapy, Combination
  • Fasting
  • Fatty Acids, Omega-3
  • Female
  • Follow-Up Studies
  • Glucose Intolerance
  • Hospitalization
  • Humans
  • Hypoglycemia
  • Hypoglycemic Agents
  • Incidence
  • Insulin, Long-Acting
  • Intention to Treat Analysis
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Triglycerides


Dive into the research topics of 'Basal insulin and cardiovascular and other outcomes in dysglycemia'. Together they form a unique fingerprint.

Cite this